rewirebio.iobenchmarks
Contested result

MPC and REVEL: Comprehensive assessment of computational algorithms in predicting cancer driver mutations and Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Comprehensive assessment of computational algorithms in predicting cancer driver mutations ranks MPC above REVEL in 10 of 10 comparisons; Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks REVEL above MPC in 7 of 7 comparisons. No other study gives a verdict, so neither is the outlier.

An automatic lead, not a finding of error. The results below are shown as published, everywhere on the site, until a reviewer decides otherwise.

Which studies agree

4 papers rank MPC above REVEL in 12 of their 24 comparisons and REVEL higher in 10; 2 are ties. Of those papers, Livesey and Marsh 2025, ProteinGym rank REVEL higher on their own (7 of 7, 1 of 1).

Papers grouped by which system they rank higher: MPC or REVELRank MPC higher: Comprehensive assessment…. Rank REVEL higher: Livesey and Marsh 2025, ProteinGym. Mixed: An openly licensed benchmark….Rank MPC higherMixedRank REVEL higherComprehensive assessment…Comprehensive assessment of computational algorithms in predicting cancer driver mutationsAn openly licensedbenchmark…An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer driversLivesey and Marsh 2025Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)ProteinGymProteinGym: Large-Scale Benchmarks for Protein Fitness Prediction and Design
  • Rank MPC higher (1): Comprehensive assessment…
  • Rank REVEL higher (2): Livesey and Marsh 2025, ProteinGym
  • Mixed (1): An openly licensed benchmark…

Each paper sits where at least two thirds of its comparisons point; Mixed means neither model reaches two thirds. The larger, outlined dot is the paper that disagrees.

Comparisons in which each paper scores MPC or REVEL higherComprehensive assessment…: MPC higher in 10, REVEL higher in 0, 0 ties. Livesey and Marsh 2025: MPC higher in 0, REVEL higher in 7, 0 ties. An openly licensed benchmark…: MPC higher in 2, REVEL higher in 2, 2 ties. ProteinGym: MPC higher in 0, REVEL higher in 1, 0 ties.Comprehensive assessment…Comprehensive assessment of computational algorithms in predicting cancer driver mutations10 MPC higher10Livesey and Marsh 2025Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)7 REVEL higher7An openly licensed benchmark…An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers2 MPC higher22 tie22 REVEL higher2ProteinGymProteinGym: Large-Scale Benchmarks for Protein Fitness Prediction and Design1 REVEL higher1
MPC higherTieREVEL higherNumbers are counts of comparisons; the outlined bar is the paper that disagrees.
Comparisons in Comprehensive assessment… (10)
ProtocolDatasetMetricMPCREVELHigher
OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)OncoKB-annotated somatic missense mutations (oncogenic, likely oncogenic and likely neutral)Accuracy (OncoKB benchmark (positive set not stated), median-score threshold), fraction0.680.67MPC
OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)OncoKB-annotated somatic missense mutations (oncogenic, likely oncogenic and likely neutral)Negative predictive value (OncoKB benchmark (positive set not stated), median-score threshold), fraction0.680.67MPC
OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)OncoKB-annotated somatic missense mutations (oncogenic, likely oncogenic and likely neutral)Precision (OncoKB benchmark (positive set not stated), median-score threshold), fraction0.680.67MPC
OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)OncoKB-annotated somatic missense mutations (oncogenic, likely oncogenic and likely neutral)Recall (OncoKB benchmark (positive set not stated), median-score threshold), fraction0.680.67MPC
OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)OncoKB-annotated somatic missense mutations (oncogenic, likely oncogenic and likely neutral)Specificity (OncoKB benchmark (positive set not stated), median-score threshold), fraction0.680.67MPC
Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Missense mutations with Ba/F3 and MCF10A cell viability calls (published and new)Accuracy (cell viability drivers versus neutral, median-score threshold), fraction0.660.64MPC
Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Missense mutations with Ba/F3 and MCF10A cell viability calls (published and new)Negative predictive value (cell viability drivers versus neutral, median-score threshold), fraction0.660.64MPC
Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Missense mutations with Ba/F3 and MCF10A cell viability calls (published and new)Precision (cell viability drivers versus neutral, median-score threshold), fraction0.660.64MPC
Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Missense mutations with Ba/F3 and MCF10A cell viability calls (published and new)Recall (cell viability drivers versus neutral, median-score threshold), fraction0.660.65MPC
Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Missense mutations with Ba/F3 and MCF10A cell viability calls (published and new)Specificity (cell viability drivers versus neutral, median-score threshold), fraction0.660.64MPC
Comparisons in Livesey and Marsh 2025 (7)
ProtocolDatasetMetricMPCREVELHigher
Livesey and Marsh 2025 clinical benchmark: pairwise AUROC win rate, ClinVar pathogenic versus gnomAD missenseLivesey and Marsh 2025 clinical set: ClinVar pathogenic versus gnomAD v4.1 missense (819 proteins)Pairwise win rate (average pairwise win rate against all other VEPs, per-protein AUROC on shared variants, ClinVar P/LP versus gnomAD v4.1 missense, proteins with at least 10 of each), percent4576REVEL
Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS setsLivesey and Marsh 2025 human DMS benchmark set (36 proteins)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, 36 human DMS sets), percent53.666.1REVEL
Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS setsLivesey and Marsh 2025 human DMS benchmark set (36 proteins)Pairwise win rate (average pairwise win rate against the five top-ranked VEPs (column top_5_winrate; the five are not listed in the table), |Spearman| with DMS on shared variants, 36 human DMS sets), percent11.613.2REVEL
Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, direct assays onlyLivesey and Marsh 2025 human DMS benchmark set (36 proteins)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, direct DMS assays only), percent57.265.6REVEL
Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, indirect assays onlyLivesey and Marsh 2025 human DMS benchmark set (36 proteins)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, indirect DMS assays only), percent50.766.3REVEL
Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions onlyLivesey and Marsh 2025 human DMS benchmark set (36 proteins)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, SNV-accessible substitutions only), percent53.666.1REVEL
Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions with gaps filledLivesey and Marsh 2025 human DMS benchmark set (36 proteins)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS, SNV-accessible substitutions, missing predictions filled with the VEP's most benign score), percent54.867.5REVEL
Comparisons in An openly licensed benchmark… (6)
ProtocolDatasetMetricMPCREVELHigher
CGC missense oncogenicity, all genes (Lee 2026, OncoCal tool_performance.tsv)Missense variants in 768 Cancer Gene Census genes with open oncogenicity labelsAUROC (CGC missense, all genes), unitless0.8230.816Tie
CGC missense oncogenicity, all genes (Lee 2026, OncoCal tool_performance.tsv)Missense variants in 768 Cancer Gene Census genes with open oncogenicity labelsAverage precision (CGC missense, all genes), unitless0.6130.652REVEL
CGC missense oncogenicity, oncogenes (gain of function) (Lee 2026, OncoCal tool_performance.tsv)Missense variants in 768 Cancer Gene Census genes with open oncogenicity labelsAUROC (CGC missense, oncogenes (gain of function)), unitless0.8420.843Tie
CGC missense oncogenicity, oncogenes (gain of function) (Lee 2026, OncoCal tool_performance.tsv)Missense variants in 768 Cancer Gene Census genes with open oncogenicity labelsAverage precision (CGC missense, oncogenes (gain of function)), unitless0.7160.739REVEL
CGC missense oncogenicity, tumour suppressors (loss of function) (Lee 2026, OncoCal tool_performance.tsv)Missense variants in 768 Cancer Gene Census genes with open oncogenicity labelsAUROC (CGC missense, tumour suppressors (loss of function)), unitless0.8730.859MPC
CGC missense oncogenicity, tumour suppressors (loss of function) (Lee 2026, OncoCal tool_performance.tsv)Missense variants in 768 Cancer Gene Census genes with open oncogenicity labelsAverage precision (CGC missense, tumour suppressors (loss of function)), unitless0.6260.618MPC
Comparisons in ProteinGym (1)
ProtocolDatasetMetricMPCREVELHigher
ProteinGym clinical substitutions, supervised predictors, average AUC (commit 144fe22)ProteinGym clinical substitution benchmark at commit 144fe22AUROC (ProteinGym clinical substitutions, supervised clinical predictors, Average_AUC over proteins), unitless0.8810.928REVEL

What disagrees

studies
2
Compared
MPC, REVEL
Study that disagrees
Other studies
Rule
Two-study conflict; unknown
Model identity
Matched across studies partly through links not yet reviewed

Follow-up

Current state: Not yet reviewed.

No one has reviewed this finding yet.

How to help resolve this

If you know why these studies disagree, for example a different population, metric or preprocessing step, or you have a corrected value, tell us through the contribution form. A reviewer checks every submission against its source before anything changes, and the step is added to the follow-up above.

Finding discrepancy-bdeb56dcc9ed582b · All contested results · How findings are made and followed up